Desirudin
As of the edition of 20 October 2026, Desirudin is a protein: marketed, first approved in 2003 (US); acts on F2; US protection ended in 2015.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Protein
- Brand name
- Iprivask
- First approved
- 4 April 2003 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Bausch Health; 2 holders in all
- Withdrawn from market
- 18 July 2014 (in some regions)
- Registered trials
- 3, 1 stopped early
- Disease areas
- Heart and blood vessels
US protection
US protection ended in 2015.
US protection ended in 2015, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Bausch Health. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Desirudin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| F2 | Prothrombin | P00734 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 2 | 1 | 0 | 1 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Canyon Pharmaceuticals | Earlier holder | 2003 to now |
| Bausch Health | Acquired holder | 2020 to now |